Literature DB >> 26131098

Surgical management of giant neurofibroma in soft tissue: a single-center retrospective analysis.

Si-Ming Yuan1, Lei Cui1, Yao Guo1, Jun Wang1, Xin-Bao Hu1, Hui-Qing Jiang1, Zhi-Jian Hong1.   

Abstract

Neurofibroma, a common benign tumor in soft tissue, continues to grow, and often appears to be giant. In this study, we retrospectively analyzed the surgical treatment of 26 patients with giant neurofibromas in our clinic in the past 10 years from Jan. 2004 to Dec. 2013. The tumors were located in the head (n = 10), trunk (n = 9), limbs (n = 5), and multi-sites (n = 2). According to the location and extent of the lesion, as well as the adjacent anatomy, surgical management was performed to partially (n = 15) or almost completely (n = 11) resect the tumor. The wounds were repaired by skin flap or skin graft. Among them, one child with a giant tumor in the scalp underwent three times of skin expander treatment, and acquired complete removal of the tumor finally without baldness. Eleven cases underwent the interventional embolization of tumor's nutrient arteries, which successfully reduced the bleeding in operation. Most of the skin flap and skin graft survived well. After operation, the appearance of the patients and the function of the limbs were improved largely. In conclusion, for the giant neurofibroma, surgical treatment effectively reduces the tumor burden, rehabilitates the appearance and function, and so improves the quality of life. Skin expandor and interventional embolization of nutrient artery can be used when appropriate.

Entities:  

Keywords:  Neurofibroma; expander; interventional embolization; operation

Year:  2015        PMID: 26131098      PMCID: PMC4483935     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  22 in total

1.  Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.

Authors:  Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander A Vinks; Alan Cantor; Bruce Korf; John Perentesis; David H Gutmann; Elizabeth Schorry; Roger Packer; Michael J Fisher
Journal:  Pediatr Blood Cancer       Date:  2014-06       Impact factor: 3.167

2.  Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors:  Brigitte C Widemann; Eva Dombi; Andrea Gillespie; Pamela L Wolters; Jean Belasco; Stewart Goldman; Bruce R Korf; Jeffrey Solomon; Staci Martin; Wanda Salzer; Elizabeth Fox; Nicholas Patronas; Mark W Kieran; John P Perentesis; Alyssa Reddy; John J Wright; AeRang Kim; Seth M Steinberg; Frank M Balis
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

3.  Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Authors:  Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander Vinks; Alan Cantor; John Perentesis; Elizabeth Schorry; Nicole Ullrich; David H Gutmann; James Tonsgard; David Viskochil; Bruce Korf; Roger J Packer; Michael J Fisher
Journal:  Neuro Oncol       Date:  2014-10-14       Impact factor: 12.300

4.  Direct assignment of the human beta B2 and beta B3 crystallin genes to 22q11.2----q12: markers for neurofibromatosis 2.

Authors:  T J Hulsebos; E K Bijlsma; A H Geurts van Kessel; R H Brakenhoff; A Westerveld
Journal:  Cytogenet Cell Genet       Date:  1991

5.  Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.

Authors:  Reinhard E Friedrich; Carolin Beer; Markus Glatzel; Christian Hagel
Journal:  Anticancer Res       Date:  2015-01       Impact factor: 2.480

6.  Precise localization of NF1 to 17q11.2 by balanced translocation.

Authors:  D H Ledbetter; D C Rich; P O'Connell; M Leppert; J C Carey
Journal:  Am J Hum Genet       Date:  1989-01       Impact factor: 11.025

7.  Spontaneous hemorrhage of a facial neurofibroma: endovascular embolization before surgical intervention.

Authors:  Krystal Lynne Tomei; Vikas Gupta; Charles J Prestigiacomo; Chirag D Gandhi
Journal:  J Craniofac Surg       Date:  2013       Impact factor: 1.046

8.  Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.

Authors:  Eric P Rahrmann; Branden S Moriarity; George M Otto; Adrienne L Watson; Kwangmin Choi; Margaret H Collins; Margaret Wallace; Beau R Webber; Colleen L Forster; Anthony E Rizzardi; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Am J Pathol       Date:  2014-05-13       Impact factor: 4.307

9.  Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.

Authors:  Jiang Wei; Marcus Freytag; Yvonne Schober; Wolfgang A Nockher; Victor F Mautner; Reinhard E Friedrich; Paul W Manley; Lan Kluwe; Andreas Kurtz
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

10.  Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.

Authors:  Jean de la Croix Ndong; Alexander J Makowski; Sasidhar Uppuganti; Guillaume Vignaux; Koichiro Ono; Daniel S Perrien; Simon Joubert; Serena R Baglio; Donatella Granchi; David A Stevenson; Jonathan J Rios; Jeffry S Nyman; Florent Elefteriou
Journal:  Nat Med       Date:  2014-07-06       Impact factor: 53.440

View more
  4 in total

1.  Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.

Authors:  Bahir H Chamseddin; La'Nette Hernandez; Dezehree Solorzano; Juan Vega; Lu Q Le
Journal:  JCI Insight       Date:  2019-04-30

2.  Cardiac overload resolved by resection of a large plexiform neurofibroma on both the buttocks and upper posterior thighs in a patient with neurofibromatosis type I: a case report.

Authors:  Taro Mikami; Yuki Honma-Koretsune; Yui Tsunoda; Shintaro Kagimoto; Yuichiro Yabuki; Jiro Maegawa; Takashi Terauchi; Shintaro Nawata; Hiroyuki Kamide; Yoshinobu Ishiwata; Tabito Kino; Teruyasu Sugano
Journal:  BMC Surg       Date:  2020-05-18       Impact factor: 2.102

3.  Surgically treated solitary giant gluteal and retroperitoneal neurofibroma: a case report.

Authors:  Xiang-qian Shen; Hui Shen; Shou-cheng Wu; Ying Lv; Hui Lu; Xiang-jin Lin
Journal:  World J Surg Oncol       Date:  2016-04-27       Impact factor: 2.754

4.  Lady with wings: a case report of giant neurofibromatosis type I.

Authors:  Suraj Maharjan; Xiucun Li; Jianli Cui; Yang Liu; Laijin Lu
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.